Revlucabtagene Autoleucel

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameRevlucabtagene Autoleucel
Drug Alias NameHBI-0101NXC-201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vectorCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsAntiphospholipid SyndromeScleroderma, SystemicLupus Erythematosus, Systemic +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHadassah Medical OrganizationImmix Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmix Biopharma IncNexcella IncHadassah Medical Organization
Inactive CompaniesN/A
Active IndicationsAntiphospholipid SyndromeScleroderma, SystemicLupus Erythematosus, Systemic +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A